stereotactic ablative radiation therapy
Recently Published Documents


TOTAL DOCUMENTS

254
(FIVE YEARS 53)

H-INDEX

19
(FIVE YEARS 5)

2021 ◽  
Vol 9 (1) ◽  
pp. 181
Author(s):  
Aws Abdulrahman Alsuhaibani ◽  
Abdullah Abdulrahman Alsuhaibani ◽  
Tareq Salah Hassan

Insulinoma is the most common pancreatic neuroendocrine tumor (NET). It is a rare disease account for 1-2% of pancreatic tumors and affect approximately up to 3 patients per million per year. complete surgical resection or debulking are standard of care option. However, surgery is associated with short and long-term post-operative morbidity and may not be appropriate for all patients. In This case we present management and cure of a case of functioning insulinoma with stereotactic ablative radiosurgery in an unfit patient for surgery.


2021 ◽  
Vol 163 ◽  
pp. S66
Author(s):  
Ronan McDermott ◽  
Emma Dunne ◽  
Yizhou Zhao ◽  
Mitchell Liu ◽  
Roy Ma ◽  
...  

2021 ◽  
Vol Volume 13 ◽  
pp. 7009-7031
Author(s):  
Davide Franceschini ◽  
Maria Ausilia Teriaca ◽  
Luca Dominici ◽  
Ciro Franzese ◽  
Marta Scorsetti

Author(s):  
Gustavo Nader Marta ◽  
Fernando F. De Arruda ◽  
Fabiana A. Miranda ◽  
Alice R.N.S. Silva ◽  
Wellington F.P. Neves-Junior ◽  
...  

2021 ◽  
pp. 100692
Author(s):  
Jonathan E. Schoenhals ◽  
Osama Mohamad ◽  
Alana Christie ◽  
Yuanyuan Zhang ◽  
Daniel Li ◽  
...  

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Dae-Myoung Yang ◽  
David A. Palma ◽  
Keith Kwan ◽  
Alexander V. Louie ◽  
Richard Malthaner ◽  
...  

Abstract Background Stereotactic ablative radiation therapy (SABR) is effective in treating inoperable stage I non-small cell lung cancer (NSCLC), but imaging assessment of response after SABR is difficult. This prospective study aimed to develop a predictive model for true pathologic complete response (pCR) to SABR using imaging-based biomarkers from dynamic [18F]FDG-PET and CT Perfusion (CTP). Methods Twenty-six patients with early-stage NSCLC treated with SABR followed by surgical resection were included, as a pre-specified secondary analysis of a larger study. Dynamic [18F]FDG-PET and CTP were performed pre-SABR and 8-week post. Dynamic [18F]FDG-PET provided maximum and mean standardized uptake value (SUV) and kinetic parameters estimated using a previously developed flow-modified two-tissue compartment model while CTP measured blood flow, blood volume and vessel permeability surface product. Recursive partitioning analysis (RPA) was used to establish a predictive model with the measured PET and CTP imaging biomarkers for predicting pCR. The model was compared to current RECIST (Response Evaluation Criteria in Solid Tumours version 1.1) and PERCIST (PET Response Criteria in Solid Tumours version 1.0) criteria. Results RPA identified three response groups based on tumour blood volume before SABR (BVpre-SABR) and change in SUVmax (ΔSUVmax), the thresholds being BVpre-SABR = 9.3 mL/100 g and ΔSUVmax = − 48.9%. The highest true pCR rate of 92% was observed in the group with BVpre-SABR < 9.3 mL/100 g and ΔSUVmax < − 48.9% after SABR while the worst was observed in the group with BVpre-SABR ≥ 9.3 mL/100 g (0%). RPA model achieved excellent pCR prediction (Concordance: 0.92; P = 0.03). RECIST and PERCIST showed poor pCR prediction (Concordance: 0.54 and 0.58, respectively). Conclusions In this study, we developed a predictive model based on dynamic [18F]FDG-PET and CT Perfusion imaging that was significantly better than RECIST and PERCIST criteria to predict pCR of NSCLC to SABR. The model used BVpre-SABR and ΔSUVmax which correlates to tumour microvessel density and cell proliferation, respectively and warrants validation with larger sample size studies. Trial registration MISSILE-NSCLC, NCT02136355 (ClinicalTrials.gov). Registered May 8, 2014, https://clinicaltrials.gov/ct2/show/NCT02136355


Sign in / Sign up

Export Citation Format

Share Document